Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy
The DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Abstract
Interferon (IFN)-alpha is a cytokine of the innate immune response that is well known for inducing behavioral alterations and has been used to study effects of cytokines on the nervous system. Limited data, however, are available on the sites of action of IFN-alpha within the brain and their relationship with specific IFN-alpha-induced symptoms. Using a longitudinal design, whole-brain metabolic activity as assessed by fluorine-18-labeled fluorodeoxyglucose uptake and positron emission tomography was examined before and 4 weeks after IFN-alpha administration in patients with malignant melanoma. Changes in metabolic activity in relevant brain regions were then correlated with IFN-alpha-induced behavioral changes. IFN-alpha administration was associated with widespread bilateral increases in glucose metabolism in subcortical regions including the basal ganglia and cerebellum. Decreases in dorsal prefrontal cortex glucose metabolism were also observed. Prominent IFN-alpha-induced behavioral changes included lassitude, inability to feel, and fatigue. Correlational analyses revealed that self-reported fatigue (specifically as assessed by the 'energy' subscale of the Visual Analog Scale of Fatigue) was associated with increased glucose metabolism in the left nucleus accumbens and putamen. These data indicate that IFN-alpha as well as other cytokines of the innate immune response may target basal ganglia nuclei, thereby contributing to fatigue-related symptoms in medically ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IFNα administration was found to be associated with increased glucose metabolism in the basal ganglia and cerebellum, which are involved in motor activity and motivation”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Capuron et al., 2007
In the citing paper
“the observed NDI increase has been interpreted as representing the inflammatory process.”
From NODDI in clinical research (2020) · cites this paper as Capuron et al., 2007
In the citing paper
“In agreement with this, cancer patients treated with IFN-α display decreased glucose metabolism in the dorsal prefrontal cortex but increased glucose metabolism in the cerebellum and basal ganglia73.”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [73]
In the citing paper
“IFN-α therapy led to reports of fatigue in a sample of patients with malignant melanoma that were positively correlated with increased glucose metabolism in the basal ganglia (the left putamen and left NAc) (Capuron et al., 2007).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Capuron et al., 2007
In the citing paper
“IFN-α therapy led to reports of fatigue in a sample of patients with malignant melanoma that were positively correlated with increased glucose metabolism in the basal ganglia (the left putamen and left NAc) (Capuron et al., 2007).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Capuron et al., 2007
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages
Cox, R. W. (1996) · Computers and Biomedical Research · doi:10.1006/cbmr.1996.0014 · Cited by 10,913
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527 · cited 1×
“Given the role of dopamine pathways in activating frontal cortex neurons (Alexander et al, 1986), altered basal ganglia and dopamine function may also contribute to the reduced metabolic activity observed in the frontal cortex following IFN-a administration.”
BackgroundForman, S. D., Cohen, J. D., Fitzgerald, M., Eddy, W. F., Mintun, M. A., & Noll, D. C. (1995) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910330508 · Cited by 3,202
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
Self-citationThe Mini-Mental State Examination
Folstein, M. F. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790060110016 · Cited by 1,936
Validity and reliability of a scale to assess fatigue
Lee, K. A., Hicks, G., & Nino-Murcia, G. (1991) · Psychiatry Research · doi:10.1016/0165-1781(91)90027-m · Cited by 1,261
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · cited 2×
“In contrast, the mood/cognitive syndrome, which develops in a smaller proportion of patients and occurs at later stages of IFN-a treatment, has been shown to be highly responsive to paroxetine administration (Capuron et al, 2002a; Capuron and Miller, 2004; Musselman et al, 2001).”
BackgroundResultSelf-citationThe primate cortico-cerebellar system: anatomy and function
Ramnani, N. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1953 · Cited by 1,011
Cytokine-induced sickness behaviour: mechanisms and implications
Konsman, J. P., Parnet, P., & Dantzer, R. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02088-9 · Cited by 999 · cited 1×
“All of these cytokines can access the brain and have profound effects on neurotransmitter metabolism, neuroendocrine function, synaptic plasticity, and behavior (Konsman et al, 2002; Raison et al, 2006).”
BackgroundCytokine‐Induced Sickness Behavior: Mechanisms and Implications
Dantzer, R. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05827.x · Cited by 801
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797 · cited 7×
“…others have indicated that hyperactivity of stress-responsive neuroendocrine pathways and disturbances in serotonin metabolism may participate in the development of the mood/cognitive syndrome during IFN-a therapy (Bonaccorso et al, 2002; Capuron and Miller, 2004; Capuron et al, 2002b, 2003a, b).”
BackgroundMethodResultInfluentialSelf-citationGao, H., Jiang, J., Wilson, B., Zhang, W., Hong, J., & Liu, B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00928.x · Cited by 687
Chaudhuri, A., & Behan, P. O. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00411-1 · Cited by 651
Cytokines and psychopathology: Lessons from interferon-α
Capuron, L., & Miller, A. H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.009 · Cited by 562 · cited 6×
“…others have indicated that hyperactivity of stress-responsive neuroendocrine pathways and disturbances in serotonin metabolism may participate in the development of the mood/cognitive syndrome during IFN-a therapy (Bonaccorso et al, 2002; Capuron and Miller, 2004; Capuron et al, 2002b, 2003a, b).”
InfluentialSelf-citationFatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors
Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200207000-00010 · Cited by 540
Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. J., Meyers, C. A., Miller, A. H., Payne, R., Reuben, J. M., Wang, X. S., et al. (2003) · Cancer · doi:10.1002/cncr.11382 · Cited by 526
Self-citationInterferon-alpha–induced changes in tryptophan metabolism
Capuron, L., Neurauter, G., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., Fuchs, D., & Miller, A. H. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00173-2 · Cited by 493
Self-citationCapuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., & Dantzer, R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000995 · Cited by 473 · cited 7×
“…others have indicated that hyperactivity of stress-responsive neuroendocrine pathways and disturbances in serotonin metabolism may participate in the development of the mood/cognitive syndrome during IFN-a therapy (Bonaccorso et al, 2002; Capuron and Miller, 2004; Capuron et al, 2002b, 2003a, b).”
BackgroundMethodResultInfluentialSelf-citationMeyers, C. A., Albitar, M., & Estey, E. (2005) · Cancer · doi:10.1002/cncr.21234 · Cited by 459
Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine
Salamone, J., Correa, M., Mingote, S., & Weber, S. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.004 · Cited by 458
The metabolic topography of parkinsonism
Eidelberg, D., Moeller, J. R., Dhawan, V., Spetsieris, P., Takikawa, S., Ishikawa, T., Chaly, T., Robeson, W., Margouleff, D., Przedborski, S., et al. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.99 · Cited by 455 · cited 1×
“Increased glucose metabolism in the basal ganglia (as seen following IFN-a administration) has been repeatedly demonstrated in PD patients (Eidelberg et al, 1994; Mentis et al, 2002; Spetsieris et al, 1995), where it is believed to reflect the degeneration of inhibitory neurocircuits related to the…”
BackgroundBonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., & Maes, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00014 · Cited by 437
Salamone, J. D., Correa, M., Mingote, S., & Weber, S. M. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035063 · Cited by 433
Inflammatory Process in Parkinsons Disease: Role for Cytokines
Nagatsu, T., & Sawada, M. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381620 · Cited by 412
Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease
Mayberg, H. S., Starkstein, S. E., Sadzot, B., Preziosi, T., Andrezejewski, P. L., Dannals, R. F., Wagner, H. N., & Robinson, R. G. (1990) · Annals of Neurology · doi:10.1002/ana.410280111 · Cited by 412
Capuron, L., Raison, C. L., Musselman, D. L., Lawson, D. H., Nemeroff, C. B., & Miller, A. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1342 · Cited by 308 · cited 1×
“…others have indicated that hyperactivity of stress-responsive neuroendocrine pathways and disturbances in serotonin metabolism may participate in the development of the mood/cognitive syndrome during IFN-a therapy (Bonaccorso et al, 2002; Capuron and Miller, 2004; Capuron et al, 2002b, 2003a, b).”
BackgroundSelf-citationMiaskowski, C., & Lee, K. A. (1999) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(99)00008-1 · Cited by 307
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy: Prevalence and Prediction
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 299
Self-citationA Cytokine-Based Neuroimmunologic Mechanism of Cancer-Related Symptoms
Lee, B.-N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., Meyers, C. A., Miller, A. H., Payne, R., Reuben, J. M., et al. (2004) · Neuroimmunomodulation · doi:10.1159/000079408 · Cited by 294
Self-citationExacerbated physical fatigue and mental fatigue in Parkinson's disease
Lou, J., Kearns, G., Oken, B., Sexton, G., & Nutt, J. (2001) · Movement Disorders · doi:10.1002/mds.1042 · Cited by 244
Anterior Cingulate Activation and Error Processing During Interferon-Alpha Treatment
Capuron, L., Pagnoni, G., Demetrashvili, M., Woolwine, B. J., Nemeroff, C. B., Berns, G. S., & Miller, A. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.03.033 · Cited by 222 · cited 1×
“…magnetic resonance imaging, we recently reported that IFN-a-induced alterations in information processing as reflected by increased activation in the dorsal anterior cingulate cortex during a task of visuo-spatial attention may also contribute to mood and anxiety symptoms (Capuron et al, 2005).”
BackgroundSelf-citationHIV dementia: the role of the basal ganglia and dopaminergic systems
Berger, J. R., & Arendt, G. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400304 · Cited by 195
Phares, T. W., Kean, R. B., Mikheeva, T., & Hooper, D. C. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7666 · Cited by 193 · cited 1×
“…loss of BBB integrity as well as upregulation of relevant adhesion molecules during a nonpathogenic CNS viral infection, suggesting that regional differences in BBB permeability may occur in the context of exposure to certain viruses or antiviral cytokines, such as IFN-a (Phares et al, 2006).”
BackgroundBenign causes of 18-FDG uptake on whole body imaging
Stadalnik, R. C., Bakheet, S. M., & Powe, J. (1998) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(98)80038-x · Cited by 191
Psychometric Testing of Fatigue Instruments for Use With Cancer Patients
Meek, P. M., Nail, L. M., Barsevick, A., Schwartz, A. L., Stephen, S., Whitmer, K., Beck, S. L., Jones, L. S., & Walker, B. L. (2000) · Nursing Research · doi:10.1097/00006199-200007000-00001 · Cited by 184
Campbell, I. L., Krucker, T., Steffensen, S., Akwa, Y., Powell, H. C., Lane, T., Carr, D. J., Gold, L. H., Henriksen, S. J., & Siggins, G. R. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01328-1 · Cited by 182
High opiate receptor binding potential in the human lateral pain system
Baumgärtner, U., Buchholz, H.-G., Bellosevich, A., Magerl, W., Siessmeier, T., Rolke, R., Höhnemann, S., Piel, M., Rösch, F., Wester, H.-J., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2005.10.033 · Cited by 175
Metabolic correlates of levodopa response in Parkinson’s disease
Feigin, A., Fukuda, M., Dhawan, V., Przedborski, S., Jackson–Lewis, V., Mentis, M. J., Moeller, J. R., & Eidelberg, D. (2001) · Neurology · doi:10.1212/wnl.57.11.2083 · Cited by 174
Functional neuroanatomy of the basal ganglia in Parkinson's disease.
Wichmann, T., & DeLong, M. R. (2003) · PubMed · Cited by 169
Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia
Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995) · Neurology · doi:10.1212/wnl.45.5.947 · Cited by 160
Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain
Shuto, H., Kataoka, Y., Horikawa, T., Fujihara, N., & Oishi, R. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01371-6 · Cited by 151
Prefrontal cortical hypometabolism during low-dose interferon alpha treatment
Juengling, F. D., Ebert, D., Gut, O., Engelbrecht, M. A., Rasenack, J., Nitzsche, E. U., Bauer, J., & Lieb, K. (2000) · Psychopharmacology · doi:10.1007/s002130000549 · Cited by 149
Capuron, L., Ravaud, A., & Dantzer, R. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200105000-00007 · Cited by 148 · cited 1×
“…slowingFa behavioral sign that often accompanies altered basal ganglia functionFwas predictive of subsequent depressive symptoms, suggesting that IFN-a-induced effects on the basal ganglia may precede changes in prefrontal cortical function and their effects on behavior (Capuron et al, 2001).”
BackgroundSelf-citationGray, F., Adle‐Biassette, H., Chrétien, F. C., de la Grandmaison, G. L., Force, G., & Keohane, C. (2001) · PubMed · Cited by 145
NEUROIMMUNOMODULATION VIA LIMBIC STRUCTURES — THE NEUROANATOMY OF PSYCHOIMMUNOLOGY
Haas, H. S., & Schauenstein, K. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00055-x · Cited by 143
Interferon-Induced Fatigue in Patients With Melanoma: A Pilot Study of Exercise and Methylphenidate
Schwartz, A. L., Thompson, J. A., & Masood, N. (2002) · Oncology Nursing Forum · doi:10.1188/02.onf.e85-e90 · Cited by 140
Reproducibility of Cerebral Glucose Metabolic Measurements in Resting Human Subjects
Bartlett, E. J., Brodie, J. D., Wolf, A. P., Christman, D. R., Laska, E., & Meissner, M. (1988) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1988.91 · Cited by 136
Mentis, M. J., McIntosh, A. R., Perrine, K., Dhawan, V., Berlin, B., Feigin, A., Edwards, C., Mattis, P., & Eidelberg, D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.746 · Cited by 136 · cited 1×
“…metabolism in the basal ganglia (as seen following IFN-a administration) has been repeatedly demonstrated in PD patients (Eidelberg et al, 1994; Mentis et al, 2002; Spetsieris et al, 1995), where it is believed to reflect the degeneration of inhibitory neurocircuits related to the loss of…”
BackgroundLou, J., Kearns, G., Benice, T., Oken, B., Sexton, G., & Nutt, J. (2003) · Movement Disorders · doi:10.1002/mds.10505 · Cited by 133
Kamata, M. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00067-x · Cited by 105
Oscillations in the basal ganglia
Wichmann, T., & DeLong, M. R. (1999) · Nature · doi:10.1038/23148 · Cited by 83
von Giesen, H.-J., Antke, C., Hefter, H., Wenserski, F., Seitz, R. J., & Arendt, G. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1601 · Cited by 81
Maddock, C., Landau, S., Barry, K., Maulayah, P., Hotopf, M., Cleare, A. J., Norris, S., & Pariante, C. M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001634 · Cited by 54 · cited 2×
“…a mood/cognitive syndrome, including depressed mood, anxiety, and attentional and memory alterations, and a neurovegetative syndrome, including fatigue (the most common IFN-a-induced symptom), anorexia, psychomotor slowing, and sleep disturbances (Capuron et al, 2002a; Maddock et al, 2005).”
BackgroundInfluentialRegulation of Neurotransmitter Interactions in the Ventral Striatum
McGINTY, J. F. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb09265.x · Cited by 53
Maquet, P., Dive, D., Salmon, É., von Frenckel, R., & Franck, G. (1990) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00842779 · Cited by 53
Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease
Leng, A., Mura, A., Feldon, J., & Ferger, B. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.077 · Cited by 46
Microglial localization of α-interferon receptor in human brain tissues
Yamada, T., & Yamanaka, I. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11452-3 · Cited by 46
Horikawa, N., Yamazaki, T., Sagawa, M., & Nagata, T. (1999) · General Hospital Psychiatry · doi:10.1016/s0163-8343(99)00026-2 · Cited by 43
Effect of interferon-α on tyrosine hydroxylase and catecholamine levels in the brain of rats
Kumai, T., Tateishi, T., Tanaka, M., WATANABÉ, M., Shimizu, H., & Kobayashi, S. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00660-3 · Cited by 40
Sunami, M., Nishikawa, T., Yorogi, A., & Shimoda, M. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00012 · Cited by 29
HIV Dementia Scale and Psychomotor Slowing--The Best Methods in Screening for Neuro-AIDS
von Giesen, H.-J., Haslinger, B. A., Rohe, S., Köller, H., & Arendt, G. (2005) · Journal of Neuropsychiatry · doi:10.1176/jnp.17.2.185 · Cited by 28
Wang, J., Zeng, X., Fan, G.-X., Yuan, Y., & Tang, J. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.12.046 · Cited by 26
Visualizing the evolution of abnormal metabolic networks in the brain using PET
Spetsieris, P. G., Moeller, J. R., Dhawan, V., Ishikawa, T., & Eidelberg, D. (1995) · Computerized Medical Imaging and Graphics · doi:10.1016/0895-6111(95)00011-e · Cited by 23
Horikawa, N., Yamazaki, T., Sagawa, M., & Nagata, T. (1999) · General Hospital Psychiatry · doi:10.1016/s0163-8343(98)00082-6 · Cited by 14
Cited by
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
Self-citationSlavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
“In another study using this same model, IFN- administration was found to be associated with increased glucose metabolism in the basal ganglia and cerebellum, which are involved in motor activity and motivation (Capuron et al., 2007).”
BackgroundImmune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
“…including the activation of the HPA axis and corticotropin-releasing hormone (CRH) and the alteration of the metabolism of key monoamines (e.g., serotonin, DA, norepinephrine) (Dantzer et al., 1999; Capuron and Miller, 2004; Raison et al., 2006; Capuron et al., 2007a; Miller et al., 2009).”
BackgroundSelf-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
“…comes from neuoroimaging studies in humans examining basal ganglia activity after administration of IFN-alpha or immune activating stimuli (e.g. LPS or typhoid vaccination) (Capuron et al., 2007, Brydon et al., 2008, Harrison et al., 2009b, Eisenberger et al., 2010, Capuron et al., 2012).”
Background
Metadata
- Authors
- Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., Berns, G. S., Nemeroff, C. B., & Miller, A. H.
- Affiliations
- Emory University (US)
- Corresponding author
- Miller, Andrew H
- ORCID
- Venue
- Neuropsychopharmacology
- Published
- 2007-02-28
- Volume
- 32
- Issue
- 11
- Pages
- 2384-2392
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2072184805
- Cited by
- 229
- References
- 70
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 7 · 2023: 10 · 2022: 5 · 2021: 9 · 2020: 15 · 2019: 10 · 2018: 17 · 2017: 12 · 2016: 18 · 2015: 17 · 2014: 8 · 2013: 14 · 2012: 22
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion)
- Funders
- Abbott Laboratories
- American Foundation for Suicide Prevention
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- American Psychiatric Institute for Research and Education
- Emory University
- National Alliance for Research on Schizophrenia and Depression
- ACADIA Pharmaceuticals
- Neurocrine Biosciences
- Centers for Disease Control and Prevention
- Pfizer Pharmaceuticals
- National Institute of Mental Health (MH 067990, R01MH067990, MH069124, K05MH069124)
- National Institute on Drug Abuse (K08DA000367, DA-00367)
- National Institute of Biomedical Imaging and Bioengineering (EB002635, R01EB002635)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Keywords
- interferon-alpha, basal ganglia, fatigue, glucose metabolism, nucleus accumbens, putamen, cerebellum, prefrontal cortex, melanoma, lassitude, immune-related adverse events
- MeSH terms
- Adult, Basal Ganglia, Behavioral Symptoms, Brain Mapping, Female, Humans, Immunologic Factors, Longitudinal Studies, Male, Middle Aged, Fatigue Syndrome, Chronic, Interferon-alpha, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.